Takeda Drops Orteronel Prostate Cancer Drug After Phase III Trials
This article was originally published in PharmAsia News
Takeda Pharmaceutical said it is dropping its TAK-700 (orteronel) drug for treating prostate cancer because it proved no better than alternatives in two Phase III trials in the U.S. and Europe.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.